Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and sign institutional review board/independent ethics committee-approved informed consent form (ICF) prior to any study-specific evaluation~* Life expectancy of at least 3 months~* ECOG performance status of 0 to 1~* ≥ 18 years at the time ICF is signed~* Adequate hematological and biological function~* Histologically or cytologically confirmed solid tumor malignancy (Part 1 only)~* Histologically or cytologically confirmed stage IIIb/IV NSCLC (Part 2 only)~Exclusion Criteria:~* Symptomatic central nervous system metastases~* Concomitant treatment with prohibited medications, e.g. other chemotherapy, radiation, hormonal treatment (excepting corticosteroids), or immunotherapy ≤ 14 days prior to CO-1.01 treatment~* Treatment with a previous regimen of CO-1.01~* Participation in another therapeutic clinical study within 14 days of enrollment or during this clinical study~* Surgical procedures ≤ 14 days prior to CO-1.01 administration~* History of allergy to gemcitabine, gemcitabine elaidate or eggs~* Known allergic/hypersensitivity reaction to cisplatin, other platinum agent, or platinum containing compounds~* Peripheral neuropathy ≥ Grade 1~* Females who are pregnant or breastfeeding~* Refusal to use adequate contraception for fertile patients~* Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study~* Any other reason the investigator considers the patient should not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CO-1.01 and Cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).